{
  "nctrialId": "HC-1258",
  "title": "A  Open-Label, Placebo-Controlled Multi-Center Study of ARH-921 (JAK inhibitor) in Patients With Heart Failure",
  "officialTitle": "A  Open-Label, Placebo-Controlled Multi-Center Study of ARH-921 (JAK inhibitor) in Patients With Heart Failure",
  "sponsor": "University Health Network",
  "indication": "Heart Failure",
  "phase": "Phase 1",
  "fileName": "HC-1258.json",
  "fileSize": 309413,
  "date": "2024-02-19",
  "completionDate": "2026-10-07",
  "drugName": "ARH-921 (JAK inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Terminated",
  "description": "This is a  open-label, placebo-controlled multi-center study designed to evaluate the efficacy and safety of ARH-921 (JAK inhibitor) in patients with Heart Failure. The study will enroll approximately 367 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 27-71 years\n- Confirmed diagnosis of Heart Failure\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}